What Should Be in Your Medical Records if You Took Tysabri?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Specific Legal Concerns

If you or a loved one took Tysabri and are now experiencing neurological symptoms like confusion, vision changes, or weakness, you may be concerned about progressive multifocal leukoencephalopathy (PML). The academic legacy of medical knowledge has long emphasized the importance of early detection and thorough documentation in such cases. This page provides a checklist of key medical records to request and review to help you stay informed about your health.

Medical Background and Risk Factors for Tysabri-Associated PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Virginia who have developed PML after Tysabri treatment, understanding the medical evidence and legal considerations—including the statute of limitations—is critical. PML is an opportunistic viral infection of the brain that typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The prescribing information for Tysabri includes a boxed warning stating that the drug increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment, and physicians must weigh expected benefits against PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation, Diagnosis, and Mechanistic Pathways

PML presents with progressive neurological deficits, including cognitive impairment, motor weakness, visual disturbances, and speech difficulties. Diagnosis typically involves brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via PCR. The timeline between Tysabri exposure and PML onset can vary, with cases reported after a few months to several years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanistic link between Tysabri and PML involves the drug's action as an alpha-4 integrin antagonist. By blocking lymphocyte migration into the central nervous system, Tysabri reduces immune surveillance, allowing JC virus reactivation and uncontrolled replication in oligodendrocytes. This immunosuppressive effect, combined with the patient's own immune status, creates a permissive environment for PML development.

Adequacy of Warnings and Legal Considerations for Virginia Patients

The boxed warning and prescribing information clearly state the PML risk and identify known risk factors. However, questions may arise regarding whether these warnings were adequately communicated to patients and whether healthcare providers fully informed patients of the risk-benefit profile. The TOUCH Prescribing Program requires patients to read a Medication Guide, understand risks, and sign an enrollment form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, some patients may argue that the warnings were insufficient or that their individual risk factors were not adequately assessed. For Virginia residents who have developed PML after Tysabri treatment, legal action may be possible against the manufacturer, Biogen, for failure to warn or design defect. The statute of limitations for personal injury claims in Virginia is generally two years from the date the injury was discovered or reasonably should have been discovered. Given the latency between Tysabri exposure and PML onset, the discovery date may be when PML is diagnosed or when symptoms become clearly attributable to the drug. Patients should consult with an attorney experienced in pharmaceutical litigation to determine the applicable deadline, as missing the statute of limitations can bar recovery.

Timeline Between Exposure and Documented Harm

The timeline from Tysabri initiation to PML diagnosis can span months to years, with risk increasing after two years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This extended latency complicates legal claims, as the injury may not manifest until well after the last dose. Virginia courts may apply the 'discovery rule,' which tolls the statute of limitations until the plaintiff knows or should know of the injury and its cause. Documentation of PML diagnosis, treatment history, and risk factor assessment is essential for establishing the timeline.

Conclusion

Tysabri-associated PML is a devastating condition with high morbidity and mortality. While the drug's labeling includes explicit warnings, affected patients in Virginia should be aware of the statute of limitations for filing claims. Prompt legal consultation is advisable to preserve rights and gather necessary medical evidence. The interplay of risk factors, treatment duration, and clinical presentation underscores the need for careful monitoring and informed decision-making.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Virginia?

In Virginia, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or reasonably should have been discovered. For Tysabri-associated PML, this may be the date of diagnosis or when symptoms are linked to the drug. Consulting an attorney promptly is crucial to avoid missing the deadline.

What are the risk factors for developing PML while on Tysabri?

Three key risk factors are identified: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors are detailed in the prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.